Inhibikase Therapeutics, Inc. (IKT:NASDAQ) closed at $1.66 on October 21, 2026, down 2.92% on the day. The stock trades 36.4% below its 52-week high of $2.61 and 24.8% above its 52-week low of $1.33. Over the past year, it gained 7.8%. Inhibikase Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 21, 2025, IKT closed higher on 108 days (43%). Its best day was December 26, 2025 (+21.21%) and its worst was November 6, 2025 (-12.35%). The stock moved 10% or more in a single session 5 times. It opened at least 5% above the previous day's high 3 times.
Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.
Find more stocks like IKT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.